Takeda Pharmaceutical Company Limited Comprehensive Income Attributable To Noncontrolling Interests
Takeda Pharmaceutical Company Limited (TAK) reported Comprehensive Income Attributable To Noncontrolling Interests of JPY 154.00 million for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Income Statement › Unrealized Gains
ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests · last filed 2025-06-25
| Period end | Comprehensive Income Attributable To Noncontrolling Interests 12 month |
|---|---|
| 2025-03-31 | 154.00M JPY 20-F · filed 2025-06-25 |
| 2024-03-31 | 173.00M JPY 20-F · filed 2025-06-25 |
| 2023-03-31 | 45.00M JPY 20-F · filed 2025-06-25 |
| 2022-03-31 | 168.00M JPY 20-F · filed 2024-06-26 |
| 2021-03-31 | 214.00M JPY 20-F · filed 2023-06-28 |
| 2020-03-31 | 150.00M JPY 20-F · filed 2022-06-29 |
| 2019-03-31 | -264.00M JPY 20-F · filed 2021-06-29 |
| 2018-03-31 | 220.00M JPY 20-F · filed 2020-06-24 |
| 2017-03-31 | -410.00M JPY 20-F · filed 2019-06-27 |